Samsung Biologics Acquires GSK US Factory for $280M to Expand Global Manufacturing

Samsung Biologics, part of Samsung Group, acquired a GSK factory in Rockville, Maryland for $280 million, adding 60,000 liters of API production capacity.

Impact

• Total capacity reaches 845,000 liters
• Positions Samsung as world's largest CDMO by capacity
• Strategic US manufacturing presence reduces geopolitical risk

Analysis

This acquisition accelerates Samsung Biologics' dominance in contract biopharmaceutical manufacturing. The US-based facility also provides supply chain diversification away from Asia, a growing concern for pharmaceutical companies post-COVID.